imusyn GmbH & Co. KG

Imusyn (founded in 2001) is a biotechnology company which specialises in alloproteomics with the objective of advancing allogeneic cellular therapies and personalised medicine. Imusyn is DIN EN ISO 13485 certified and can thus provide a comprehensive service to customers in developing in vitro diagnostic medical devices under the European regulations. Our services are fully integrated and supervised by our Quality Management Department to ensure that each individual development step will contribute towards achieving the most efficient and compliant manufacturing process possible. Imusyn currently comprises an interdisciplinary team of 20 scientists, technicians and project managers experienced in development, production, and quality management in the fields of life sciences. To date Imusyn has produced more than 30 products to advance allogeneic cellular therapies, is currently producing a number of CE-marked diagnostic assays and has also been involved in numerous assay developments throughout Europe and the US. Our mission is to develop and produce outstanding diagnostic tests in the field of transfusion medicine and organ transplantation. A recent publication details the use of imusyn's IVD DaraEx plus to mitigate the interference of anti-CD38 antibodies in the IAT ⧉. Our innovative, high-throughput service for you to confirm your target peptides, e.g.